| Inducing and exploiting vulnerabilities for the treatment of liver cancer C Wang, S Vegna, H Jin, B Benedict, C Lieftink, C Ramirez, ... Nature 574 (7777), 268-272, 2019 | 318 | 2019 |
| SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo S Mainardi, A Mulero-Sánchez, A Prahallad, G Germano, A Bosma, ... Nature medicine 24 (7), 961-967, 2018 | 306 | 2018 |
| Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer KJ Frank, A Mulero-Sanchez, A Berninger, L Ruiz-Canas, A Bosma, ... Cell Reports Medicine 3 (11), 2022 | 21 | 2022 |
| Paradoxical activation of oncogenic signaling as a cancer treatment strategy MH Dias, A Friskes, S Wang, JM Fernandes Neto, F van Gemert, ... Cancer Discovery, OF1-OF26, 2024 | 10 | 2024 |
| Genetic and compound screens uncover factors modulating cancer cell response to indisulam Z Pogacar, K Groot, F Jochems, MDS Dias, A Mulero-Sánchez, B Morris, ... Life Science Alliance 5 (9), 2022 | 7 | 2022 |
| Importance of genetic screens in precision oncology A Mulero-Sánchez, Z Pogacar, L Vecchione ESMO open 4 (3), e000505, 2019 | 7 | 2019 |
| Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma A Mulero‐Sánchez, CFA Ramirez, A du Chatinier, H Wang, SJI Koomen, ... Molecular Oncology 17 (6), 964-980, 2023 | 5 | 2023 |
| Combined SHP2 and ERK inhibition for the treatment of KRAS-driven pancreatic ductal adenocarcinoma KJ Ciecielski, A Mulero-Sánchez, A Berninger, LR Cañas, A Bosma, ... bioRxiv, 2021.12. 14.472574, 2021 | 2 | 2021 |
| 1630P Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers AC Kanhailal, A Mulero-Sánchez, JE Knikman, A Bosma, R Bernards, ... Annals of Oncology 34, S902-S903, 2023 | 1 | 2023 |
| All roads lead to SHP2 A Mulero-Sánchez Utrecht University, 2023 | | 2023 |
| Abstract B53: Differential response of distinct KRAS mutants to SHP2 inhibition S Mainardi, A Bosma, A Mulero-Sánchez, R Bernards Molecular Cancer Research 18 (5_Supplement), B53-B53, 2020 | | 2020 |
| Differential response of distinct KRAS mutants to SHP2 inhibition. S Mainardi, A Bosma, A Mulero-Sanchez, R Bernards MOLECULAR CANCER RESEARCH 18 (5), 77-78, 2020 | | 2020 |
| Identification of molecular determinants of vinorelbine resistance in BRAF (V600E) mutated chemorefractory metastatic colorectal cancer patients L Vecchione, I Beumer, A Mulero-Sanchez, M Snel, F Pietrantonio, ... Cancer Research 78 (13_Supplement), 1823-1823, 2018 | | 2018 |
| PO-019 PTPN11 is a therapeutic target in KRAS mutant lung cancer S Mainardi, A Mulero-Sánchez, A Prahallad, G Germano, A Bosma, ... ESMO Open 3, A234-A235, 2018 | | 2018 |
